US EditionAstraZeneca's Enhertu shows promise in early-stage breast cancer treatment
Enhertu improved three-year disease-free survival to 92.4% and achieved a 67.3% complete response rate with fewer severe side effects, clinical trial data show.
- On Saturday, AstraZeneca and Daiichi Sankyo announced Enhertu produced strong results in two pivotal early-stage studies presented at the European Society for Medical Oncology Congress.
- Enhertu, an antibody-drug conjugate described as `guided missiles`, targets HER2-positive breast cancer, which accounts for about 15% to 20% of all breast cancers.
- In one late-stage trial, patients with high-risk early HER2-positive breast cancer achieved a 67.3% pathologic complete response versus 56% for standard chemotherapy, with fewer side effects.
- Combined sales of Enhertu by AstraZeneca and Daiichi Sankyo reached $3.75 billion last year, and the drug is approved in more than 75 countries.
- Company leaders argued the ADC approach can displace chemotherapy in multiple settings, with Susan Galbraith and Ken Keller urging focus on affordability and reimbursement.
12 Articles
12 Articles
Enhertu pushes into early breast cancer, as antibody-drug conjugates move up the line
BERLIN — Enhertu has become a staple treatment in advanced breast cancer, but new data presented Saturday at the European Society for Medical Oncology’s annual conference show the drug can have powerful benefits for patients when given earlier in the disease, opening the door to higher rates of cures. For Enhertu’s makers, AstraZeneca and Daiichi Sankyo, the findings from the two trials could expand the drug, already a blockbuster, to tens of t…
The results of the Phase 3 clinical trial 'DESTINY Breast11' have shown that treating patients with high-risk early HER2+ breast cancer before surgery with the antibody-pharmaceutical conjugate (ADC) trastuzumab deruxtecan improves the complete pathological response to standard chemotherapy treatment.
Enhertu could move into 'curative' breast cancer setting on the strength of Phase 3 data
BERLIN – AstraZeneca and Daiichi Sankyo unveiled details of a late-stage success for their blockbuster drug Enhertu in an early form of breast cancer ahead of surgery where the companies believe it could help cure ...
Coverage Details
Bias Distribution
- 75% of the sources are Center
Factuality
To view factuality data please Upgrade to Premium
